Altered purinergic P2X7 and A

Adenosine receptors CD39 Host defense Leishmaniasis Macrophages P2X7 receptors Parasite-host interaction Schistosomiasis

Journal

Biomedical journal
ISSN: 2320-2890
Titre abrégé: Biomed J
Pays: United States
ID NLM: 101599820

Informations de publication

Date de publication:
03 Mar 2024
Historique:
received: 06 03 2023
revised: 05 01 2024
accepted: 25 02 2024
medline: 6 3 2024
pubmed: 6 3 2024
entrez: 5 3 2024
Statut: aheadofprint

Résumé

The occurrence of co-infections during schistosomiasis, a neglected tropical disease, with other parasites have been reported suggesting an impaired host immune defense. Macrophage purinergic P2X7 receptor (P2X7R) play an important role against intracellular pathogens. Therefore, we investigated the P2X7R-mediated phagocytosis and killing capacity of Leishmania amazonensis by macrophages during schistosomiasis in vitro and in vivo. Swiss and C57BL/6 (Wild type) and P2X7R The pre-treatment of macrophages with the P2X7R antagonist (A74003) or TGF-β reduced the phagocytosis index, mimicking the phenotype of cells from S. mansoni-infected mice and P2X7R Altogether, the altered P2X7R and A

Sections du résumé

BACKGROUND BACKGROUND
The occurrence of co-infections during schistosomiasis, a neglected tropical disease, with other parasites have been reported suggesting an impaired host immune defense. Macrophage purinergic P2X7 receptor (P2X7R) play an important role against intracellular pathogens. Therefore, we investigated the P2X7R-mediated phagocytosis and killing capacity of Leishmania amazonensis by macrophages during schistosomiasis in vitro and in vivo.
METHODS METHODS
Swiss and C57BL/6 (Wild type) and P2X7R
RESULTS RESULTS
The pre-treatment of macrophages with the P2X7R antagonist (A74003) or TGF-β reduced the phagocytosis index, mimicking the phenotype of cells from S. mansoni-infected mice and P2X7R
CONCLUSIONS CONCLUSIONS
Altogether, the altered P2X7R and A

Identifiants

DOI: 10.1016/j.bj.2024.100713 PMID: 38442854
pubmed: 38442854
pii: S2319-4170(24)00016-7
doi: 10.1016/j.bj.2024.100713
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100713

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest none.

Auteurs

Maria Luiza Thorstenberg (ML)

Laboratory of Biochemical and Molecular Pharmacology, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil.

Monique Daiane Andrade Martins (MDA)

Laboratory of Immunophysiology, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Brazil.

Nathália Ferreira Oliveira (NF)

Laboratory of Biochemical and Molecular Pharmacology, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil.

Matheus Macedo L V Monteiro (MMLV)

Laboratory of Biochemical and Molecular Pharmacology, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil.

GustavoR C Santos (GC)

Brazilian Doping Control Laboratory (LBCD - LADETEC / IQ), Universidade Federal do Rio de Janeiro, Brazil.

HenriqueM Gualberto Pereira (HG)

Brazilian Doping Control Laboratory (LBCD - LADETEC / IQ), Universidade Federal do Rio de Janeiro, Brazil.

Luiz Eduardo Baggio Savio (LEB)

Laboratory of Immunophysiology, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Brazil.

Robson Coutinho-Silva (R)

Laboratory of Immunophysiology, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Brazil.

Claudia Lucia Martins Silva (CLM)

Laboratory of Biochemical and Molecular Pharmacology, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil. Electronic address: silva.claudiamartins.ufrj@gmail.com.

Classifications MeSH